Cargando…
In vivo genome editing restores hemostasis in a mouse model of hemophilia
Autores principales: | Li, Hojun, Haurigot, Virginia, Doyon, Yannick, Li, Tianjian, Wong, Sunnie Y., Bhagwat, Anand S., Malani, Nirav, Anguela, Xavier M., Sharma, Rajiv, Ivanciu, Lacramiora, Murphy, Samuel L., Finn, Jonathan D., Khazi, Fayaz R., Zhou, Shangzhen, Paschon, David E., Rebar, Edward J., Bushman, Frederic D., Gregory, Philip D., Holmes, Michael C., High, Katherine A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152293/ https://www.ncbi.nlm.nih.gov/pubmed/21706032 http://dx.doi.org/10.1038/nature10177 |
Ejemplares similares
-
Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
por: Haurigot, Virginia, et al.
Publicado: (2010) -
Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs
por: Callan, Mary Beth, et al.
Publicado: (2016) -
Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
por: Kizilocak, Hande, et al.
Publicado: (2019) -
RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A
por: Lin, Wen-yi, et al.
Publicado: (2021) -
Oracle or false prophet? Can we predict AAV efficacy based on preexisting antibody titers?
por: Anguela, Xavier M., et al.
Publicado: (2019)